SB 239063 is a potent and selective p38 MAP kinase inhibitor (IC50 = 44 nM for p38??). SB 239063 displays > 220-fold selectivity over ERK, JNK1 and other kinases; ~ 3-fold more selective than SB 203580. SB 239063 reduces inflammatory cytokine production and is neuroprotective following oral administration in vivo.
More Information Supplier PageSB 239063 is a potent and selective p38 MAP kinase inhibitor (IC50 = 44 nM for p38??). SB 239063 displays > 220-fold selectivity over ERK, JNK1 and other kinases; ~ 3-fold more selective than SB 203580. SB 239063 reduces inflammatory cytokine production and is neuroprotective following oral administration in vivo.
More Information Supplier PageSB 239063 is a potent and selective p38 MAP kinase inhibitor (IC50 = 44 nM for p38??). SB 239063 displays > 220-fold selectivity over ERK, JNK1 and other kinases; ~ 3-fold more selective than SB 203580. SB 239063 reduces inflammatory cytokine production and is neuroprotective following oral administration in vivo.
More Information Supplier PageSYN115 is an orally administered, potent and selective inhibitor of the adenosine 2a (A2a) receptor that is being developed initially for the treatment of Parkinson?€?s disease, but may also have utility in other CNS disorders.
More Information Supplier PageSYN115 is an orally administered, potent and selective inhibitor of the adenosine 2a (A2a) receptor that is being developed initially for the treatment of Parkinson?€?s disease, but may also have utility in other CNS disorders.
More Information Supplier PageSotrastaurin is a protein kinase C inhibitor for the prevention of transplant rejection and treatment of psoriasis.
More Information Supplier Page
